MedWatch

Demant downgrades after revenue disappoints

Hearing aid firm Demant has downgraded its full-year guidance after its revenue for the first six months of 2022 failed to meet analyst expectations. (Updated)

Photo: Demant / PR

Demant’s H1 revenue came to DKK 9.4bn (USD 1.28bn), compared to an analyst consensus estimate of DKK 9.6bn (USD 1.31bn). Its net result came in at DKK 1.05bn (USD 143.5m), compared to the analyst consensus estimate of DKK 1.15bn (USD 157.2m). This has led to a downgrade.

The company now expects 4-6% organic growth compared to a previous 5-9%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs